Emergent BioSolutions (NYSE: EBS) reported Q3 Revenue for the quarter at $271 million versus the consensus estimate of $237.43 million.

GUIDANCE:

Emergent BioSolutions sees FY2023 revenue of $1-1.1 billion, versus the consensus of $1.04 billion.

For earnings history and earnings-related data on Emergent BioSolutions (EBS) click here.